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BY-NC-ND license (http://creativecoSummary Issues related to small-for-size grafts in living donor liver transplantation (LDLT)
are highly important. The neutrophil lymphocyte ratio (NLR) has been reported to be an inex-
pensive index of systemic inflammation for various diseases. We retrospectively evaluated the
relationship between NLR and clinical course of 61 adult LDLT recipients in our institute until
post-operative day 14. Patients were classified into two groups based on the graft volume
divided by standard liver volume, as over 35% of graft volume divided by standard liver volume
(GV/SLV) (Group L; n Z 55) and under 35% of GV/SLV (Group S; n Z 6). No differences were
seen in background of the patients between the two groups. Also, absolute neutrophil,
lymphocyte and platelet counts in both the groups showed no significant differences. In
contrast, the NLR between the groups differed significantly from post-operative day 3 to 10,
being higher in the Group S. In addition, the incidence of prolonged hyperbilirubinemia and
small for size graft syndrome differed significantly between the two groups. Therefore, the
elevation of post-operative NLR in the smaller graft group reflect suggestive pathophysiology
of endothelial injuries that related to small for size graft syndrome in LDLT.
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Table 1 Baseline characteristics of the recipients,
donors, grafts, and operations.
Factors Group L
(n Z 55)
Group S
(n Z 6)
p
Recipient
Age (y) 52.9  9.7 50.7  8.7 0.58
Male/female 33/22 3/3 0.68
MELD score 19.1  12.3 20.2  3.7 0.83
Indication 0.03
Cholestatic
diseases
13 0
Fulminant
hepatic failure
1 1
HCC 27 0
Liver cirrhosis 12 5
Others 2 0
Donor and graft
Age (y) 46.5  6.9 40.2  13.0 0.25
Male/female 32/23 4/2 0.70
GV/SLV (%) 48.8  9.9 32.5  2.0 <0.001
GRWR (%) 0.98  0.26 0.62  0.06 <0.01
Left lobe/right
lobe/others
38/16/1 4/0/2 0.56
Operation
Operation time
(min)
947  252 1078  233 0.23
Blood loss (mL) 6836  12,023 10,885  9918 0.36
GRWR Z graft-to-recipient body-weight ratio; GV/SLV Z graft
volume divided by standard liver volume; HCCZ hepatocellular
carcinoma; MELD Z model for end-stage liver disease.
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Many reports have described issues associated with graft
size in living-donor liver transplantation (LDLT).1,2 Graft
size affects the small-for-size (SFS) graft syndrome, which
is often catastrophic and needs to be avoided.3 The prin-
cipal pathogenesis of the SFS syndrome is thought to be
excessively increased portal flow and the subsequent in-
duction of graft sinusoidal endothelial injury.2 However,
the symptoms of the SFS syndrome cannot be completely
avoided, even when an appropriate ratio of graft size to
portal inflow is obtained. Therefore, a greater under-
standing of the underlying pathophysiology is important for
overcoming the SFS syndrome.
Complete blood count is an inexpensive and indispens-
able test following major surgeries, including LDLT. Thus
far, the platelet count and its time-serial changes have
been the focus of attention, given its reported relationship
with postoperative morbidity and mortality.4 Similarly, the
neutrophil-to-lymphocyte ratio (NLR) is an inexpensive
index of systemic inflammation.5 Preoperative NLR has
been investigated as a prognostic factor of hepatocellular
carcinoma (HCC) in LDLT recipients.6 In addition, a rela-
tionship between prognosis and NLR has been reported in
patients with colorectal, lung, and ovarian cancers, as well
as in HCC patients.7e10 Further, NLR can predict the survival
in patients of acute coronary syndrome treated by percu-
taneous coronary intervention and coronary artery bypass
grafting.11,12 However, to date, no reports have analyzed
the postoperative NLR in LDLT recipients. Here, we
describe a retrospective pilot study to evaluate the rela-
tionship between NLR and adult SFS grafts, along with an
analysis of other clinical factors.
2. Methods
Between January 1999 and December 2013, 61 patients
underwent their first adult LDLT at Kanazawa University
Hospital, Kanazawa, Japan. These patients were included
in the present study after obtaining an approval from the
Institutional Review Board of Kanazawa University Hospital.
All living donors were evaluated by contrast-enhanced
abdominal computed tomography with using three-dimen-
sional image-analyzing system (SYNAPSE VINCENT; Fuji
Film, Tokyo, Japan). The results of the computed tomog-
raphy were used to calculate whole-liver volumetry, liver
graft volume, and residual liver in the donor. The standard
liver volume was calculated using the formula developed by
Urata et al.13 The actual graft weight of the procured graft
was measured on the back table in the operating room and
was defined as graft volume (GV). Then, the graft size was
evaluated as the GV/standard liver volume (GV/SLV) ratio
and the graft-to-recipient body-weight ratio.
The transplant procedures for both donors and re-
cipients have previously been reported.14 Hepatic arterial
reconstruction was performed using a surgical microscopic
procedure. Biliary reconstruction was routinely conducted
in a duct-to-duct fashion. Portal vein pressure during
surgery was not measured, and concomitant splenectomy
for inflow modulation was not performed during this
period.After the transplant, the immunosuppressive therapy
started with tacrolimus (Prograf; Astellas Pharma, Tokyo,
Japan) and corticosteroids. The tacrolimus dose was
adjusted to achieve a trough level of 10e15 ng/mL for 2
weeks following the transplant. Thereafter, the target
trough level was gradually reduced to approximately 7 ng/
mL. The corticosteroids were administered as an initial
dose of 2 mg/kg/d, which was tapered gradually. The
principle of postoperative managements about the trans-
plant recipient was not differed according to the graft size.
The recorded clinical data, including preoperative gen-
eral demographics, the model for end-stage liver disease
(MELD) score, graft weight, postoperative changes in com-
plete blood count, prothrombin timeeinternational
normalized ratio, total bilirubin levels, C-reactive protein,
and total amount of drained ascites fluid at postoperative
Days (POD) 1, POD 3, POD 5, POD 7, POD 10, and POD 14
were analyzed. NLR was calculated as the absolute
neutrophil count divided by the absolute lymphocyte count.
The MELD score was calculated with the formula reported
by Kamath et al.15 Further, the occurrence of adverse
clinical events and complications, including infections,
acute cellular rejection, or relaparotomy, was retrospec-
tively analyzed during the postoperative hospital stay for
LDLT. Both pre- and postoperative infectious complications
included surgical site infection defined as above Grade IIIa
of the ClavieneDindo classification, clinically treated
pneumonia, bacteremia, and other infectious episodes.16
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steroid-treated cases, as well as histologically proven ones.
The SFS syndrome is defined as the criteria of the report
from Soejima et al.3
To analyze the relationship between SFS graft and other
clinical factors, the patients were divided into two groups
according to the GV/SLV, as over 35% GV/SLV (Group L) and
under 35% GV/SLV (Group S). The parametric variables were
compared using unpaired Student t test, while the
nonparametric variables were compared using Chi-square
analysis. The survival probability of the recipients was
determined by the KaplaneMeier method. A p value < 0.05
was considered statistically significant. All statistical ana-
lyses were performed with SPSS version 20 (SPSS Inc., Chi-
cago, IL, USA).
3. Results
The baseline characteristics of the recipients, donors,
grafts, and operations are listed in Table 1. No differences
were seen with respect to age, gender, or MELD scores
between the two groups. The indications of liver trans-
plantation differed significantly between the two groups.
Further, the mean GV/SLV and graft-to-recipient body-
weight ratio between the two groups showed significant
differences, being 48.8  9.9% and 0.98  0.26% in Group L,
and 32.5  2.0% (p < 0.001) and 0.62  0.06% (p < 0.01) in
Group S, respectively.Figure 1 Changes in the absolute numbers of (A) neutrophils, (B
ratio in the recipients using graft volume/standard liver volume u
graft volume/standard liver volume over 35% graft group (Group L;
between the two groups were significant at postoperative Day 1, Da
Day 5 (p < 0.01). NLR Z neutrophil-to-lymphocyte ratio; POD Z pThe neutrophil and lymphocyte absolute counts in
Groups L and S did not differ significantly (Figures 1A and
1B); further, the platelet counts also showed no significant
differences (Figure 1C). However, the NLR showed signifi-
cant differences between the two groups from POD 3 to
POD 10 (Figure 1D). The post-transplantation prothrombin
timeeinternational normalized ratio was not significantly
different between the two groups, except on POD 1
(Figure 2A). By contrast, the total bilirubin levels differed
significantly between the two groups from POD 3 to POD 14
(Figure 2B). The C-reactive protein in Groups L and S did not
differ significantly (Figure 2C).
According to the postoperative clinical course, the
incidence of post-transplantation complications (i.e., pro-
longed hyperbilirubinemia and SFS graft syndrome) differed
significantly between the two groups. However, the inci-
dence of other postoperative complications, including
acute cellular rejection, infection, graft loss, and relapar-
otomy because of postoperative bleeding, bowel perfora-
tion, or vascular complication, was not statistically
different between the groups (Table 2).
4. Discussion
LDLT is an important therapeutic modality for patients
suffering from end-stage liver disease. However, following
LDLT, problems related to the SFS graft syndrome remain
unresolved. Many reports have described various issues) lymphocytes, (C) platelets, and (D) neutrophil-to-lymphocyte
nder 35% graft group (Group S; closed bars) and in those using
open bars). The differences in neutrophil-to-lymphocyte ratio
y 7, and Day 10 (p < 0.05), as well as at postoperative Day 3 and
ostoperative day.
Figure 2 Changes in (A) prothrombin timeeinternational normalized ratio, (B) serum total bilirubin level, and (C) C-reactive
protein in recipients using graft volume/standard liver volume under 35% graft group (Group S; closed bars) and in those using graft
volume/standard liver volume over 35% graft group (Group L; open bars). The difference in prothrombin timeeinternational
normalized ratio between the two groups was significant at postoperative Day 1 (p < 0.05). Further, the differences in the total
bilirubin levels between the two groups were significant at postoperative Day 3, Day 5, Day 7, and Day 14 (p < 0.05), as well as at
postoperative Day 10 (p < 0.01). CRPZ C-reactive protein; PODZ postoperative day; PTeINRZ prothrombin timeeinternational
normalized ratio; T-Bil. Z total bilirubin.
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specific postoperative findings has been still difficult.
One of the most important factors related to the SFS
graft-associated symptoms has been reported to be sinu-
soidal endothelial injury due to various reasons, such as
ischemia/reperfusion, usage of immunosuppressant agents,
and excessive portal vein pressure.17 Endothelial injury is
reported to cause extensive inflammatory changes, which
strongly affect the blood-coagulation system.18 Coagulo-
pathies cause microcirculatory disturbances in the graft
and impaired graft function. In this report, we used NLR to
evaluate the severity of inflammation in LDLT recipients,
demonstrating statistically significant differences in the
early postoperative period in the small graft group.
NLR has been reported to have a relationship with the
clinical course in various diseases, such as solid tumors
(including HCC before liver transplantation) and acute
coronary syndrome.7e12 In patients with myocardial
infarction, the elevation of NLR might be related to
impaired microvascular perfusion due to rheological
changes. In our study, pathophysiological changes con-
cerning post-transplantation NLR are suggested to have a
resemblance to these vascular injuries, because the graft is
exposed to similar ischemia/reperfusion injuries to acute
coronary syndrome, and also, excessive shear stress forsinusoidal endothelial cell, which is unavoidable in LDLT
using SFS graft. Thus, we speculate that the mechanism of
NLR elevation is due to the induction of strong inflamma-
tory changes by these vascular injuries.
In the domain of vascular diseases, neutrophilia is itself
a prognostic factor.19 Therefore, neutrophil counts are
suggested to have a strong relationship with vascular
endothelial cell injury. We have previously reported that
the neutrophil elastase inhibitor (sivelestat) has a sup-
pressive effect on hepatic ischemia/reperfusion injury,
suggesting the effectiveness and importance of suppressing
neutrophil activation.20 By contrast, excessive and persis-
tent suppression of neutrophils can lead to infections; thus,
appropriate suppression is considered important in the
clinical setting.
The relationship between inflammatory changes of the
endothelium and activation of neutrophils and platelets is
very important.21 As suggested in the present study,
neutrophil activation is an important pathophysiology of
graft sinusoidal endothelial injury in LDLT. In damaged si-
nusoids, activated neutrophils and platelets migrate to the
space of Disse. Moreover, platelet aggregation is observed
in this condition; we named this phenomenon “extrava-
sated platelet aggregation.”22 As mentioned previously,
various transplant-related pathophysiologies can cause
Table 2 Factors concerning postoperative complications
after living-donor liver transplantation.
Factors Group L
(n Z 55)
Group S
(n Z 6)
p
Infections 8 (14.5) 1 (16.7) 0.64
Acute cellular
rejection
12 (21.8) 0 (0.0) 0.46
Bilirubin on POD
14 > 10 mg/dL
10 (18.2) 4 (66.7) <0.05
Ascites on POD
14 > 1000 mL
13 (23.6) 1 (16.7) 0.90
PTeINR on POD
14 > 1.5
11 (20.0) 2 (33.3) 0.82
Small-for-size graft
syndrome
0 (0.0) 2 (33.3) <0.01
Biliary complications 10 (18.2) 0 (0.0) 0.57
Vascular complications 7 (12.7) 0 (0.0) 0.80
Relaparotomy during
postoperative hospital
stay
16 (29.1) 4 (66.7) 0.16
Graft loss within 1 year
postoperatively
10 (18.2) 3 (50.0) 0.20
Data are presented as n (%).
POD Z postoperative day; PTeINR Z prothrombin
timeeinternational normalized ratio.
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platelet aggregation and sequential graft dysfunction.
For LDLT using SFS graft, splenectomy is the most com-
mon surgical method of inflow modulation. Its beneficial
effects are considered mostly to be due to reduced portal
venous flow to the smaller vascular bed.23 However, it is
possible that other mechanisms are involved in the bene-
ficial effects of splenectomy, as suggested by the influence
of lymphocytic functionality and differentiation.24 In addi-
tion, beneficial immunological modulation by portal venous
infusion of prostaglandin E1 (PGE1) therapy applied in ABO-
incompatible transplantation has been reported.25 PGE1
acts not only on portal venous pressure decompression, but
also by immunological modulatory functions. Further, PGE1
is suggested to protect graft microcirculation via endothe-
lial cytoprotection by cyclic adenosine monophosphate.26
Thus, our present results support speculations about re-
lationships between graft size, sinusoidal endothelial
injury, immunological reaction, graft microcirculation, and
postoperative clinical course.
The effects of small intestinal congestion induced by
portal venous hypertension should not be ignored in the
pathophysiology of the SFS graft syndrome. Congestion of
the small intestine has been reported to induce mucosal
apoptosis in an experimental model.27 Such intestinal injury
via tumor necrosis factor-alpha leads to inflammation and
immunological activation, which affect the neutrophil
activation and lymphocyte interactions.28 Further, preser-
ving the small intestinal immunity is important in the
setting of portal venous congestion induced by SFS grafts in
LDLT.
The small number of presented cases is a limitation of
this retrospective study. The small sample size affected
statistical power of this study, because postoperativecourse of LDLT recipient affected various pathophysiolog-
ical factors. However, NLR is an easily collected and
measured biomarker. Moreover, the elevation of the NLR in
the smaller graft group reflects a suggestive pathophysi-
ology of endothelial injuries that related to SFS graft syn-
drome in LDLT. Further studies are required to establish its
utility, and enhance our understanding of the relationship
between graft size and elevation of the NLR.
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